Concepedia

Author

K. Chin

The Cancer Institute Hospital

Also Known As

K Chin, K. Chin, K.W. Chin, K.W.T.K. Chin, Keisyo Chin, Kelly Yuen Wai Chin

33

Publications

396

Citations

8

H-Index

25

Concepts

All Affiliations

The Cancer Institute HospitalNational Cancer Center Hospital EastSungkyunkwan UniversitySamsung Medical Center
KC

About

K. Chin is an author at The Cancer Institute Hospital specializing in medicine, radiation oncology, and cancer therapeutics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

6

6

337

2

Health Sciences

2

2

50

3

Gastroenterology

2

2

29

4

Allergy

1

1

34

5

Nutrition

1

1

34

K. Chin

×

8

Publications

381

Citations

8

H-Index

YearCitations

Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer

Yasuhiro Matsumura, Mitsukazu Gotoh, Kei Muro,

Annals of Oncology

2004

249

The histamine content of oriental foods

K. Chin, Margarita M. Garriga, Dean D. Metcalfe

Food and Chemical Toxicology

1989

34

Association of p53 Protein Expression with Responses and Survival of Patients with Locally Advanced Esophageal Carcinoma Treated with Chemoradiotherapy

Kenji Muro, A. Ohtsu, Narikazu Boku,

Japanese Journal of Clinical Oncology

1996

27

Leukocytoclastic vasculitis with purpura and renal failure induced by the anti-epidermal growth factor receptor antibody panitumumab: a case report

Hitomi Kamo, Eiji Shinozaki, Takanobu Sugase,

Journal of Medical Case Reports

2019

17

Irinotecan plus S-1 (IRIS) versus S-1 alone as first line treatment for advanced gastric cancer: Preliminary results of a randomized phase III study (GC0301/TOP-002)

K. Chin, Hiroyasu Iishi, Hiromi Imamura,

Journal of Clinical Oncology

2007

16

Nivolumab versus chemotherapy in advanced esophageal squamous cell carcinoma (ESCC): The phase III ATTRACTION-3 study

Byoung Chul Cho, Ken Kato, Masanobu Takahashi,

Annals of Oncology

2019

14

gastrointestinal tumours, non-colorectal Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy: Phase III GOLD study

Y-J. Bang, Narikazu Boku, K. Chin,

Annals of Oncology

2016

13

2749 Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with recurrent or refractory ovarian cancer: A phase Ib trial reporting safety and clinical activity

ML Disis, M.R. Patel, S. Pant,

European Journal of Cancer

2015

11

Page 1